Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Glaukos Corporation
This is a prospective, multi-center, single arm, open-label clinical trial of the iS3 system. Up to 65 qualified subjects will be implanted with three G2-W stents in one eye and will be followed for 12 months postoperatively.
Age
45–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of refractory open-angle glaucoma (including pigmentary and pseudoexfoliative glaucoma) that is uncontrolled despite medical therapy and/or prior conventional incisional intraocular glaucoma surgeries.
Phakic or pseudophakic.
Males or females, 45 years of age or older.
You may not be if
Traumatic, uveitic, neovascular, or angle-closure; or glaucoma associated with vascular disorders.
Active corneal inflammation or edema.
Retinal disorders not associated with glaucoma.
Clareo Health | Investigation of the Glaukos® Trabecular Micro-Bypass System, Model iS3, in Subjects With Refractory Glaucoma
